BAYZF - Bayer Amgen looked at Iveric before agreeing to Astellas sale - report
2023-05-23 13:17:29 ET
- Bayer ( OTCPK:BAYZF ) and Amgen ( AMGN ) were interested in Iveric Bio ( NASDAQ: ISEE ) before it agreed to a $5.9 billion sale to Astellas ( OTCPK:ALPMF ).
- Iveric ( ISEE ) detailed in a proxy filed on Tuesday that it reached out to five parties about a bidding process, and a sixth also communicated interest in a strategic transaction. Iveric ( ISEE ) agreed to a $40 per share all cash sale to Astellas late last month.
- Bayer ( OTCPK:BAYZF ) met with Iveric ( ISEE ) at JPMorgan's Healthcare conference earlier this year and expressed interest in acquiring the ex-US rights to Zimura, making a written offer on April 13, according to an Endpoints News report , which cited a source familiar.
- Amgen ( AMGN ) was one of the several companies that looked at Iveric ( ISEE ), though it declined to make an offer, Endpoints reported.
- Iveric ( ISEE ) rose 1.4% on Tuesday.
For further details see:
Bayer, Amgen looked at Iveric before agreeing to Astellas sale - report